NASDAQ:INVA - Innoviva Stock Price, Price Target & More

$14.77 +0.12 (+0.82 %)

(As of 04/26/2018 11:06 AM ET)

Previous Close$14.65

Today's Range$14.12 - $14.78

52-Week Range$11.02 - $17.99

Volume618,424 shs

Average Volume1.00 million shs

Market Capitalization$1.61 billion

P/E Ratio12.56

Dividend YieldN/A

Beta2.17

About Innoviva (NASDAQ:INVA)

Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI). It has Long-Acting Beta2 Agonist collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California.

Receive INVA News and Ratings via Email

Sign-up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:INVA

CUSIP88338T10

Webwww.inva.com

Phone650-238-9600

Debt

Debt-to-Equity Ratio-2.37%

Current Ratio5.77%

Quick Ratio5.77%

Price-To-Earnings

Trailing P/E Ratio12.56

Forward P/E Ratio6.56

P/E GrowthN/A

Sales & Book Value

Annual Sales$217.22 million

Price / Sales6.92

Cash Flow$1.4027 per share

Price / Cash10.53

Book Value($2.38) per share

Price / Book-6.21

Profitability

EPS (Most Recent Fiscal Year)$1.17

Net Income$134.14 million

Net Margins61.76%

Return on Equity-48.93%

Return on Assets35.25%

Miscellaneous

Employees12

Outstanding Shares101,820,000

How to Become a New Pot Stock Millionaire

Innoviva (NASDAQ:INVA) Frequently Asked Questions

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

How were Innoviva's earnings last quarter?

Innoviva (NASDAQ:INVA) announced its quarterly earnings data on Wednesday, April, 25th. The biotechnology company reported $0.35 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.50 by $0.15. The biotechnology company earned $52.40 million during the quarter, compared to analysts' expectations of $71.84 million. Innoviva had a net margin of 61.76% and a negative return on equity of 48.93%. The company's revenue for the quarter was up 29.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.19 EPS. View Innoviva's Earnings History.

What price target have analysts set for INVA?

6 equities research analysts have issued 1 year price targets for Innoviva's shares. Their predictions range from $8.00 to $17.00. On average, they anticipate Innoviva's share price to reach $13.40 in the next twelve months. View Analyst Ratings for Innoviva.

Who are some of Innoviva's key competitors?

Some companies that are related to Innoviva include Valeant Pharmaceuticals International (VRX), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), United Therapeutics (UTHR), Galápagos (GLPG), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP) and Blueprint Medicines (BPMC).

Who are Innoviva's key executives?

Innoviva's management team includes the folowing people:

Mr. Eric d'Esparbes, Interim Principal Exec. Officer, Sr. VP & CFO (Age 50)
Dr. Theodore J. Witek Jr., Sr. VP & Chief Scientific Officer (Age 60)
Mr. George B. Abercrombie RPh, MBA, Sr. VP & Chief Commercial Officer (Age 63)
Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VP
Dr. Kevin Kwok, Head of Talent Acquisition & Strategy

Has Innoviva been receiving favorable news coverage?

News headlines about INVA stock have trended somewhat positive this week, according to Accern. The research group ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Innoviva earned a news sentiment score of 0.11 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 47.48 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Innoviva?

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innoviva's stock price today?

One share of INVA stock can currently be purchased for approximately $14.77.

How big of a company is Innoviva?

Innoviva has a market capitalization of $1.61 billion and generates $217.22 million in revenue each year. The biotechnology company earns $134.14 million in net income (profit) each year or $1.17 on an earnings per share basis. Innoviva employs 12 workers across the globe.

How can I contact Innoviva?

Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]

MarketBeat Community Rating for Innoviva (INVA)

Community Ranking:		2.3 out of 5 ( )
Outperform Votes:		195 (Vote Outperform)
Underperform Votes:		223 (Vote Underperform)
Total Votes:		418

MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe INVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Innoviva (NASDAQ:INVA) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

6 Wall Street analysts have issued ratings and price targets for Innoviva in the last 12 months. Their average twelve-month price target is $13.40, suggesting that the stock has a possible downside of 9.28%. The high price target for INVA is $17.00 and the low price target for INVA is $8.00. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.17	2.00	2.00	2.00
Ratings Breakdown:	1 Sell Rating(s) 3 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 3 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 3 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 2 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$13.40	$13.40	$13.00	$13.00
Price Target Upside:	9.28% downside	8.59% downside	0.46% downside	6.00% downside

Innoviva (NASDAQ:INVA) Consensus Price Target History

Price Target History for Innoviva (NASDAQ:INVA)

Innoviva (NASDAQ:INVA) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/19/2018	Berenberg Bank	Initiated Coverage	Buy		Low
2/9/2018	Stifel Nicolaus	Reiterated Rating	Hold	$17.00	High
11/20/2017	Deutsche Bank	Initiated Coverage	Hold	$13.00	N/A
10/24/2017	Robert W. Baird	Reiterated Rating	Hold	$13.00	N/A
10/23/2017	Cowen	Set Price Target	Buy	$16.00	N/A
10/6/2017	Morgan Stanley	Reiterated Rating	Underweight	$7.00 -> $8.00	N/A

(Data available from 4/26/2016 forward)

Innoviva (NASDAQ:INVA) Earnings History and Estimates Chart

Earnings by Quarter for Innoviva (NASDAQ:INVA)

Innoviva (NASDAQ:INVA) Earnings Estimates

Current Year EPS Consensus Estimate: $2.25 EPS
Next Year EPS Consensus Estimate: $2.85 EPS

Innoviva (NASDAQ INVA) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/25/2018	Q1 2018	$0.50	$0.35	$71.84 million	$52.40 million	View	N/A
2/8/2018	Q4 2017	$0.49	$0.50	$67.41 million	$69.52 million	View	Listen
10/25/2017	Q3 2017	$0.34	$0.21	$57.18 million	$48.64 million	View	N/A
7/26/2017	Q2 2017	$0.28	$0.30	$50.53 million	$58.60 million	View	N/A
4/27/2017	Q1 2017	$0.27	$0.15	$47.66 million	$40.50 million	View	N/A
2/9/2017	Q4 2016	$0.19	$0.22	$40.72 million	$43.60 million	View	Listen
10/27/2016	Q316	$0.19	$0.16	$38.71 million	$33.30 million	View	Listen
7/28/2016	Q216	$0.12	$0.17	$31.13 million	$32.47 million	View	Listen
4/28/2016	Q116	$0.09	$0.04	$28.61 million	$24.17 million	View	Listen
2/3/2016	Q415	$0.01	$0.04	$20.17 million	$22.80 million	View	N/A
10/28/2015	Q315	($0.03)	($0.04)	$15.23 million	$13.56 million	View	Listen
7/29/2015	Q2	($0.0630)	($0.07)	$10.90 million	$10.70 million	View	Listen
5/6/2015	Q115	($0.08)	($0.09)	$8.64 million	$6.90 million	View	Listen
2/18/2015	Q414	($0.14)	($0.14)	$5.42 million	$7.30 million	View	N/A
10/30/2014	Q314	($0.15)	($0.19)	$5.06 million	$1.00 million	View	N/A
8/18/2014		($0.53)	($0.18)			View	N/A
8/6/2014	Q214	($0.53)	($0.18)	$4.39 million	$0.93 million	View	N/A
5/6/2014	Q114	($0.53)	($0.62)	$4.52 million	$0.17 million	View	N/A
2/6/2014	Q413	($0.38)	($0.46)	$6.03 million	$1.60 million	View	N/A
10/24/2013	Q313	$0.69	($0.44)	$3.08 million	$0.44 million	View	N/A
7/25/2013	Q2 2013	($0.46)	($0.37)	$1.43 million	$1.33 million	View	N/A
4/25/2013	Q1 2013	($0.38)	($0.39)	$2.71 million	$1.34 million	View	N/A
2/12/2013	Q4 2012	($0.36)	($0.33)	$3.88 million	$5.80 million	View	N/A
10/30/2012		($0.39)	($0.37)			View	N/A
7/31/2012		($0.42)	($0.42)			View	N/A
4/26/2012		$1.02	$0.93			View	N/A
2/9/2012		($0.38)	($0.45)			View	N/A
10/27/2011		($0.33)	($0.37)			View	N/A
7/28/2011		($0.27)	($0.31)			View	N/A
4/28/2011	Q1 2011	($0.28)	($0.28)			View	N/A
2/15/2011	Q4 2010	($0.28)	($0.25)			View	N/A
10/21/2010	Q3 2010	($0.27)	($0.29)			View	N/A
7/22/2010	Q2 2010	($0.27)	($0.28)			View	N/A
4/21/2010	Q1 2010	($0.28)	($0.35)			View	N/A
2/11/2010	Q4 2009	($0.34)	($0.35)			View	N/A
10/27/2009	Q3 2009	($0.34)	($0.35)			View	N/A
7/23/2009	Q2 2009	($0.33)	($0.35)			View	N/A
4/22/2009	Q1 2009	($0.29)	($0.29)			View	N/A
2/12/2009	Q4 2008	($0.36)	($0.26)			View	N/A
10/23/2008	Q3 2008	($0.35)	($0.34)			View	N/A
7/24/2008	Q2 2008	($0.48)	($0.36)			View	N/A
4/21/2008	Q1 2008	($0.47)	($0.49)			View	N/A
2/14/2008	Q4 2007	($0.56)	($0.54)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Innoviva (NASDAQ:INVA) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2015	quarterly	$0.25	7.01%	9/8/2015	9/10/2015	9/30/2015
5/7/2015	quarterly	$0.25	6.43%	6/10/2015	6/12/2015	6/30/2015
2/24/2015	quarterly	$0.25	5.85%	3/10/2015	3/12/2015	3/31/2015
10/31/2014	quarterly	$0.25	6.24%	11/21/2014	11/25/2014	12/23/2014
8/6/2014	quarterly	$0.25		8/26/2014	8/28/2014	9/18/2014

(Data available from 1/1/2013 forward)

Innoviva (NASDAQ INVA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.60%
Institutional Ownership Percentage: 75.28%

Insider Trading History for Innoviva (NASDAQ:INVA)

Institutional Ownership by Quarter for Innoviva (NASDAQ:INVA)

Innoviva (NASDAQ INVA) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/21/2018	Eric Desparbes	Insider	Sell	5,378	$16.52	$88,844.56
2/21/2018	George B Abercrombie	VP	Sell	8,000	$16.51	$132,080.00
12/4/2017	Michael W Aguiar	Insider	Sell	12,022	$13.13	$157,848.86	980,907
11/21/2017	Eric Desparbes	CFO	Sell	15,285	$13.28	$202,984.80	337,027
11/21/2017	George B Abercrombie	VP	Sell	5,215	$13.26	$69,150.90	263,866
8/21/2017	Eric Desparbes	CFO	Sell	1,825	$12.20	$22,265.00	344,993
5/22/2017	Eric Desparbes	CFO	Sell	1,825	$11.85	$21,626.25	352,588
5/22/2017	Theodore J Jr. Witek	VP	Sell	7,815	$12.01	$93,858.15	251,968
2/21/2017	Eric Desparbes	CFO	Sell	1,825	$12.07	$22,027.75	356,121
11/22/2016	Theodore L Witek Jr	VP	Sell	3,700	$10.84	$40,108.00	157,131
11/21/2016	Eric Desparbes	CFO	Sell	1,800	$10.89	$19,602.00
8/22/2016	Eric Desparbes	CFO	Sell	3,700	$11.77	$43,549.00	239,893
5/18/2016	James L Tyree	Director	Sell	813	$10.47	$8,512.11	50,697
5/11/2015	Plc Glaxosmithkline	Major Shareholder	Buy	85,579	$1,369,260.00	$117,179,901,540.00
8/13/2014	Junning Lee	VP	Sell	53,424	$22.50	$1,202,040.00
8/12/2014	Bradford J Shafer	SVP	Sell	28,156	$22.13	$623,092.28
8/11/2014	Bradford J Shafer	SVP	Sell	27,108	$22.12	$599,628.96
9/12/2013	Rick Winningham	CEO	Sell	22,353	$40.03	$894,790.59	690,106
7/30/2013	Mathai Mammen	SVP	Sell	7,000	$36.51	$255,570.00
6/7/2013	Bradford J Shafer	SVP	Sell	31,038	$35.04	$1,087,571.52
5/29/2013	David L Brinkley	Insider	Sell	3,808	$35.01	$133,318.08
5/13/2013	David L Brinkley	Insider	Sell	16,129	$40.33	$650,482.57
8/7/2012	Michael W Aguiar	CFO	Sell	60,000	$27.04	$1,622,400.00

(Data available from 1/1/2013 forward)

Innoviva (NASDAQ INVA) News Headlines

Source:

Date	Headline
	BRIEF-Innoviva Reports Q1 Adjusted Earnings Per Share $0.35 www.reuters.com - April 26 at 9:16 AM
	Innoviva: 1Q Earnings Snapshot finance.yahoo.com - April 26 at 9:16 AM
	Innoviva Reports First Quarter 2018 Financial Results finance.yahoo.com - April 26 at 9:16 AM
	$76.03 Million in Sales Expected for Innoviva (INVA) This Quarter www.americanbankingnews.com - April 26 at 6:10 AM
	Innoviva (INVA) Downgraded to Hold at Zacks Investment Research www.americanbankingnews.com - April 25 at 11:36 AM
	Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients With COPD finance.yahoo.com - April 24 at 4:40 PM
	Innoviva (INVA) Receives Average Recommendation of "Hold" from Analysts www.americanbankingnews.com - April 24 at 1:30 AM
	$0.57 EPS Expected for Innoviva (INVA) This Quarter www.americanbankingnews.com - April 24 at 1:14 AM
	Innoviva (INVA) Research Coverage Started at Berenberg Bank www.americanbankingnews.com - April 19 at 11:46 AM
	Innoviva (INVA) & GlaxoSmithKline plc (GSK) Highlight NEJM Publication of Landmark IMPACT Study Showing ... www.streetinsider.com - April 19 at 9:29 AM
	Innoviva (INVA) Lowered to "Buy" at BidaskClub www.americanbankingnews.com - April 18 at 10:06 AM
	Innoviva (INVA) Scheduled to Post Earnings on Wednesday www.americanbankingnews.com - April 18 at 3:28 AM
	Adjusted Price Targets For This Bio-Pharmaceutical Holding Company: More Than 20% Upside seekingalpha.com - April 17 at 4:51 PM
	Innoviva (INVA) Upgraded by Zacks Investment Research to "Buy" www.americanbankingnews.com - April 17 at 11:04 AM
	Innoviva (INVA) Stock Rating Reaffirmed by Stifel Nicolaus www.americanbankingnews.com - April 15 at 10:58 AM
	Cowen Reiterates $16.00 Price Target for Innoviva (INVA) www.americanbankingnews.com - April 15 at 9:31 AM
	Innoviva (INVA) Upgraded to "Strong-Buy" at Zacks Investment Research www.americanbankingnews.com - April 14 at 8:35 PM
	Innoviva Inc.: Buy This Small-Cap Biopharma Royalty Holding Company With 50% Upside seekingalpha.com - April 10 at 4:27 PM
	Innoviva Inc (INVA) Expected to Post Quarterly Sales of $73.83 Million www.americanbankingnews.com - April 9 at 4:28 AM
	Innoviva (INVA) Rating Increased to Buy at ValuEngine www.americanbankingnews.com - April 8 at 11:49 AM
	Innoviva Inc (INVA) Expected to Post Earnings of $0.53 Per Share www.americanbankingnews.com - April 7 at 1:10 AM
	Innoviva (INVA) Lowered to "Hold" at Zacks Investment Research www.americanbankingnews.com - April 4 at 12:02 AM
	Innoviva Target of Unusually Large Options Trading (INVA) www.americanbankingnews.com - April 3 at 7:35 AM
	Biotech Stock Tests Buy Zone, Gets New Approval For Asthma Drug Relvar Ellipta finance.yahoo.com - April 2 at 4:29 PM
	Innoviva Inc (INVA) Given Consensus Rating of "Hold" by Analysts www.americanbankingnews.com - March 30 at 1:32 AM
	Breo Ellipta (GlaxoSmithKline/Innoviva) Drug Analysis 2018 - ResearchAndMarkets.com www.businesswire.com - March 29 at 4:27 PM
	March Growth Stock Opportunities finance.yahoo.com - March 28 at 4:24 PM
	Zacks Investment Research Downgrades Innoviva (INVA) to Sell www.americanbankingnews.com - March 25 at 11:01 AM
	BidaskClub Upgrades Innoviva (INVA) to "Strong-Buy" www.americanbankingnews.com - March 24 at 6:13 PM
	Zacks: Brokerages Anticipate Innoviva Inc (INVA) Will Announce Quarterly Sales of $73.83 Million www.americanbankingnews.com - March 23 at 7:56 AM
	Innoviva (INVA) Upgraded to Buy by ValuEngine www.americanbankingnews.com - March 18 at 10:28 PM
	Innoviva (INVA) versus Teligent (TLGT) Head-To-Head Contrast www.americanbankingnews.com - March 15 at 3:46 PM
	Have Investors Priced In Innoviva Inc’s (NASDAQ:INVA) Growth? finance.yahoo.com - March 10 at 9:40 AM
	$73.83 Million in Sales Expected for Innoviva Inc (INVA) This Quarter www.americanbankingnews.com - March 5 at 1:48 AM
	Innoviva Inc (INVA) Receives Average Rating of "Hold" from Brokerages www.americanbankingnews.com - March 5 at 1:30 AM
	Zacks: Analysts Expect Innoviva Inc (INVA) Will Announce Earnings of $0.54 Per Share www.americanbankingnews.com - March 3 at 11:14 PM
	Contrasting Bristol-Myers Squibb (BMY) and Innoviva (INVA) www.americanbankingnews.com - February 28 at 1:30 AM
	Innoviva Inc (INVA) Shares Sold by Spark Investment Management LLC www.americanbankingnews.com - February 26 at 3:02 PM
	Innoviva Inc (INVA) Holdings Lifted by Smith Asset Management Group LP www.americanbankingnews.com - February 25 at 2:28 PM
	Innoviva Inc (INVA) Holdings Boosted by Systematic Financial Management LP www.americanbankingnews.com - February 25 at 11:38 AM
	Innoviva Inc (INVA) VP Sells $132,080.00 in Stock www.americanbankingnews.com - February 22 at 7:08 PM
	Eric Desparbes Sells 5,378 Shares of Innoviva Inc (INVA) Stock www.americanbankingnews.com - February 22 at 7:08 PM
	How Do Analysts See Innoviva Inc (NASDAQ:INVA) Performing In The Years Ahead? finance.yahoo.com - February 19 at 9:03 AM
	Innoviva (INVA) Upgraded to "B" by TheStreet www.americanbankingnews.com - February 18 at 9:22 PM
	$0.52 EPS Expected for Innoviva Inc (INVA) This Quarter www.americanbankingnews.com - February 15 at 5:10 AM
	GSK Submits IMPACT Data To EU To Support Trelegy Ellipta's Expanded Labelling www.nasdaq.com - February 14 at 9:08 AM
	Drug company Innoviva settles with activist hedge fund Sarissa -sources finance.yahoo.com - February 13 at 9:07 AM
	Innoviva (INVA) Rating Increased to Hold at Zacks Investment Research www.americanbankingnews.com - February 11 at 9:36 AM
	Contrasting Innoviva (INVA) and Eyegate Pharmaceuticals (EYEG) www.americanbankingnews.com - February 10 at 1:24 PM
	Innoviva (INVA) Rating Reiterated by Stifel Nicolaus www.americanbankingnews.com - February 9 at 1:04 PM

Innoviva (NASDAQ:INVA) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Innoviva (NASDAQ:INVA) Income Statement, Balance Sheet and Cash Flow Statement

Innoviva (NASDAQ INVA) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff